Markets

Monday 6/25 Insider Buying Report: DOVA, ABBV

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy - they expect to make money. So let's look at two noteworthy recent insider buys.

On Thursday, Dova Pharmaceuticals' Director, Steven M. Goldman, made a $151,100 purchase of DOVA, buying 5,000 shares at a cost of $30.22 a piece. So far Goldman is in the green, up about 13.3% on their buy based on today's trading high of $34.23. Dova Pharmaceuticals is trading up about 3.8% on the day Monday. Before this latest buy, Goldman purchased DOVA at 3 other times during the past twelve months, for a total investment of $1.79M at an average of $19.41 per share.

And at AbbVie, there was insider buying on Wednesday, by Director Edward J. Rapp who purchased 1,013 shares for a cost of $98.63 each, for a trade totaling $99,909. Before this latest buy, Rapp made one other purchase in the past year, buying $281,782 shares at a cost of $70.45 a piece. AbbVie Inc is trading off about 0.7% on the day Monday. Investors have the opportunity to pick up ABBV at a price even lower than Rapp did, with the stock changing hands as low as $92.61 at last check today which is 6.1% below Rapp's purchase price.

VIDEO: Monday 6/25 Insider Buying Report: DOVA, ABBV

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

DOVA ABBV

Other Topics

Investing